New psoriasis pill shows promise in early trial
Disease control
Not yet recruiting
This phase 2 study tests whether a new drug called RAP-103, taken as a pill once or twice daily for 8 weeks, can improve skin symptoms and quality of life in 90 adults aged 18-70 with moderate-to-severe psoriasis. Participants are randomly assigned to receive one of two doses of …
Phase: PHASE2 • Sponsor: Clarent Biopharma, Inc. • Aim: Disease control
Last updated May 17, 2026 02:22 UTC